XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2

Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Information [Abstract]

Schedule of Segment Information

Our chief operating decision-maker is our President and CEO.

		During the Three-Month Period Ended March 31, 2024
		Scours				Mastitis				Other				Total
Product sales		$	7,220,641			$	36,936			$	—			$	7,257,577
Costs of goods sold			4,923,548				38,670				—				4,962,218
Gross margin			2,297,093				(1,734	)			—				2,295,359
Product development expense			29,495				1,202,941				30,114				1,262,550
Sales and marketing expenses			669,739				131,184				—				800,923
Administrative expenses			—				—				531,938				531,938
Operating expenses			699,234				1,334,125				562,052				2,595,411
NET OPERATING INCOME (LOSS)		$	1,597,859			$	(1,335,859	)		$	(562,052	)		$	(300,052	)

		During the Three-Month Period Ended March 31, 2023
		Scours				Mastitis				Other				Total
Product sales		$	3,411,232			$	35,295			$	—			$	3,446,527
Costs of goods sold			3,103,958				41,794				—				3,145,752
Gross margin			307,274				(6,499	)			—				300,775
Product development expenses			291				1,076,344				33,733				1,110,368
Sales and marketing expenses			690,544				188,883				—				879,427
Administrative expenses			—				—				567,019				567,019
Operating expenses			690,835				1,265,227				600,752				2,556,814
NET OPERATING (LOSS)		$	(383,561	)		$	(1,271,726	)		$	(600,752	)		$	(2,256,039	)

		Scours				Mastitis				Other				Total
Total Assets as of March 31, 2024		$	24,160,698			$	17,550,907			$	1,339,443			$	43,051,048
Total Assets as of March 31, 2023		$	21,519,208			$	18,253,991			$	3,349,988			$	43,123,187
Depreciation and amortization expense during the three-month period ended March 31, 2024		$	338,919			$	318,718			$	19,863			$	677,500
Depreciation and amortization expense during the three-month period ended March 31, 2023		$	323,257			$	317,624			$	17,948			$	658,829
Capital Expenditures during the three-month period ended March 31, 2024		$	39,474			$	30,882			$	—			$	70,356
Capital Expenditures during the three-month period ended March 31, 2023		$	571,736			$	110,430			$	—			$	682,166

		During the Year Ended December 31, 2023
		Scours				Mastitis				Other				Total
Product sales		$	17,293,933			$	177,736			$	—			$	17,471,669
Costs of goods sold			13,453,514				148,871				—				13,602,385
Gross margin			3,840,419				28,865				—				3,869,284
Product development expense			11,103				4,242,329				141,420				4,394,852
Sales and marketing expenses			2,447,137				641,078				—				3,088,215
Administrative expenses			—				—				2,134,295				2,134,295
Operating expenses			2,458,240				4,883,407				2,275,715				9,617,362
NET OPERATING INCOME (LOSS)		$	1,382,179			$	(4,854,542	)		$	(2,275,715	)		$	(5,748,078	)

		During the Year Ended December 31, 2022
		Scours				Mastitis				Other				Total
Product sales		$	18,411,949			$	154,558			$	1,455			$	18,567,962
Costs of goods sold			10,754,189				136,347				28,647				10,919,183
Gross margin			7,657,760				18,211				(27,192	)			7,648,779
Product development expenses			66,346				4,317,921				109,605				4,493,872
Sales and marketing expenses			1,871,926				1,318,107				—				3,190,033
Administrative expenses			—				—				2,263,817				2,263,817
Operating expenses			1,938,272				5,636,028				2,373,422				9,947,722
NET OPERATING INCOME (LOSS)		$	5,719,488			$	(5,617,817	)		$	(2,400,614	)		$	(2,298,943	)

		Scours				Mastitis				Other				Total
Total Assets as of December 31, 2023		$	24,735,413			$	17,827,839			$	1,244,850			$	43,808,102
Total Assets as of December 31, 2022		$	20,539,523			$	18,315,492			$	6,005,634			$	44,860,649
Depreciation and amortization expense during the year ended December 31, 2023		$	1,365,988			$	1,287,600			$	86,032			$	2,739,620
Depreciation and amortization expense during the year ended December 31, 2022		$	1,169,011			$	1,263,318			$	62,912			$	2,495,241
Capital Expenditures during the year ended December 31, 2023		$	1,096,819			$	795,694			$	—			$	1,892,513
Capital Expenditures during the year ended December 31, 2022		$	3,513,336			$	414,486			$	47,452			$	3,975,274

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration